Elevated plasma levels of the endogenous nitric oxide (NO) synthase inhibitor asymmetric dimethylarginine (ADMA) contribute to endothelial dysfunction and seem to be a predictor for cardiovascular mortality. Elevated ADMA plasma concentrations have been demonstrated in patients with hypertension. However, the plasma concentrations of ADMA in white coat hypertension (WCH) has not been previously studied. The aim of this study was to evaluate ADMA in WCH and compare with normotensive (NT) and hypertensive (HT) patients. We also evaluated the relation between ADMA and NO in these three groups. For this purpose, 34 NT, 34 white coat hypertensive (clinical hypertension and ambulatory daytime blood pressure o135/85 mmHg) and 34 HT patients were recruited in this study. The subjects were matched for age, gender, body mass index (BMI) and the patients with smoking habit, dyslipidaemia and diabetes mellitus were excluded. The ADMA levels were determined by high performance liquid chromatography. Plasma ADMA levels were significantly higher in WCH group than in the NT group (3.2170.49 lmol/l vs 2.8470.58 lmol/l, P ¼ 0.046). It was significantly higher in the HT group than in the NTs (4.2470.38 lmol/l, Po0.001). There was also a significant difference between the HT and WCH groups (Po0.001). The WCH subjects had significantly higher levels of NO than the HTs (41.6872.23 vs 32.1872.68 lmol/l; Po0.001) and significantly lower values than the NTs (48.247 4.29 lmol/l; Po0.001). In WCH and HT group, there was a negative correlation between ADMA and NO (r ¼ À0.515, P ¼ 0.003 and r ¼ À0.389, P ¼ 0.034, respectively). In NT subjects, there was no correlation between these two parameters (r ¼ À0.287, P ¼ 0.124). The correlation between ADMA and NO was stronger in WCH group than in HT group. Although NO levels in HT patients were lower than WCHs and ADMA levels were higher in HT patients than WCHs, the negative correlation of these two parameters were more pronounced in WCH group. Decreased NO and increased ADMA levels in WCH may indicate endothelial dysfunction. Our data indicate also that WCH represent an intermediate group between NT and HT when endothelial dysfunction is concerned.
Introduction
The endothelium plays an important role in the control of vascular tone by releasing several vasoactive substances, such as nitric oxide (NO). In addition to its action as a vasodilator, NO inhibits platelet aggregation, leukocyte adhesion, and smooth muscle cell proliferation.
1,2
Endothelial dysfunction is common in patients with different cardiovascular risk factors, that is, diabetes mellitus, 3 hypercholesterolaemia, 4 hyperhomocysteinaemia 5 and hypertension. 6 Several factors have been proposed to explain endothelial dysfunction such as reduction of the activity and/ or expression of the endothelial nitric oxide synthase (eNOS) and/or increased vascular formation of oxygen-derived free radicals. 7 There is growing evidence that increased levels of the endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) may contribute to endothelial dysfunction. 8 In recent studies, it has been demonstrated that patients with hypertension, 9, 10 hyperlipidaemia, 11 hyperhomocysteinaemia, 12 coronary artery disease 13 have increased plasma levels of ADMA.
There is no agreement about the prognosis of the patients with white coat hypertension (WCH). Some authors say that it is an innocent clinical situation, 14, 15 whereas others found that it is associated with increased risk for cardiovascular disease. 16, 17 Clinical studies on endothelial dysfunction in WCH are also controversial. 18, 19 ADMA, which represent a novel risk factor for the development of endothelial dysfunction and a predictor for cardiovascular mortality, has not been previously studied in WCH. In this study, we investigated the concentrations of ADMA in patients with WCH, and compared them to hypertensive (HT) and normotensive (NT) patients. We also evaluated the relation of ADMA and NO in NT, WCH, and HT subjects.
Materials and methods
The study group consisted of a total of 102 subjects, 34 with WCH (17 males, 17 females) aged 49711 years, 34 sustained HTs (15 males, 19 females) aged 47711 years and 34 NT control subjects (16 males, 18 females) aged 48710 years. The groups were matched for age and gender (Table 1) . Subjects with other risk factors for atherosclerosis (LDL4130 mg/ dl, diabetes mellitus, BMI420 kg/m 2 , smoking) and subjects having signs or symptoms of atherosclerotic vascular disease and other endocrine diseases or alcoholism are not included. Patients using drugs that may effect blood pressure and lipid metabolism were also excluded. All patients were free of concomitant vascular and renal diseases (serum creatinine41.3 mg/dl), malignancy and connective tissue diseases. The procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975.
Blood pressure measurements
Measurements of brachial artery pressures in the patients referred to our outpatient clinic because of high blood pressure (diastolic pressure 490 mmHg) were obtained by a nurse with a mercury sphygmomanometer, which was standardized in accordance with the approval of American and British Hypertension Society and World Health Organization. Measurements were obtained with the subject in the sitting position after resting for 20-30 min. 20 Korotkoff phase I was used to determine the systolic pressure and phase V for diastolic pressure. Measurements were performed on three different days within 5 days. The average of three measurements were taken as the mean systolic and diastolic pressures. An ambulatory 24-h arterial blood pressure recording was performed in patients whose diastolic pressure was found to be higher than 90 mmHg in the outpatient department, with an instrument (A and D Engineering, TM-2421), which was appoved and suggested by European Society of Hypertension. 21 Measurements were performed as British Society of Hypertension suggested on the left arm. 22 According to the results of the ambulatory measurement, patients were classified as white coat vs sustained hypertension groups. WCH was defined as clinical hypertension and daytime ambulatory blood pressure less than 135/85 mmHg. Patients with the daytime ambulatory diastolic blood Table 1 Characteristics of the groups NT: normotensive group; HT: hypertensive group; WHC: white coat hypertensive group. P (1-2) The relationship between NT and WCH; P (2-3)
The relationship between WCH and HT; P (3-1) The relationship between HT and NT. NS: Nonsignificant. Table 2 Ambulatory blood pressure measurements of the groups NT: normotensive group; HT: hypertensive group; WCH: white coat hypertensive group; SBP: systolic blood pressure; DBP: diastolic blood pressure; P (1-2) The relationship between NT and WCH; P (2-3) The relationship between WCH and HT; P (3-1) The relationship between HT and NT; NS: Nonsignificant.
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Laboratory investigations
Whole blood (10 ml) was sampled from an indwelling cannula into EDTA tubes following an overnight fast and the plasma separated by centrifugation at 2000 g. The plasma was stored at À701C until assay.
NO Plasma concentration of NO was estimated using commercially available colorimetric assey (Roche, Cat. No.1 756 281). 23 In this method, nitrate is reduced to nitrite by reduced nicotinamide adenine dinucleotide phosphate (NADPH) in the presence of enzyme nitrate reductase (NR). The nitrite formed reacts with sulfanilamide and N-(1-naphthyl)-ethylene-diamine dihydrochloride to give red-violet diazo dye. The diazo dye is measured on the basis of its absorbance in the visible range at 540 nm. The coefficients of intra and interassay variations for NO levels were 4.9% (n ¼ 15) and 5.6% (n ¼ 13), respectively. ADMA ADMA was determined by sandwich ELISA procedure (Cardio-Vasics, ADMA ELISA Kit, CA, USA). 24 The coefficients of intra and interassay variations for ADMA were 4.1% (n ¼ 10) and 7.8% (n ¼ 10), respectively.
Statistical analysis
The values of selected variables were defined as mean7s.d. The NO and ADMA values of the groups were compared with one-way ANOVA (Tukey HSD). The relation between NO and ADMA levels was evaluated with Pearson's correlation test. P-value o0.05 was considered statistically significant.
Results
Basic characteristics and ambulatory blood pressure values of the groups are given in Tables 1 and 2. Patients with WCH has similar ambulatory blood pressure values with NTs.
Plasma ADMA levels were significantly higher in WCH group than in the NT group (3.2170.49 vs 2.8470.58 mmol/l, P ¼ 0.046). It was also significantly higher in the HT group than in the NTs (4.2470.38 mmol/l, Po0.001). There was significant difference between the HT and WCH groups (Po0.001). The WCH subjects had significantly higher levels of NO than the HT (41.6872.23 vs 32.1872.68 mmol/l; Po0.001) and significantly lower values than the NT (48.2474.29 mmol/l; Po0.001). Plasma NO and ADMA levels of the three groups are given in Table 3 .
There was a strong negative correlation between ADMA and NO levels in both groups (r ¼ À0.728, Po0.001). In WCH and HT groups, there was a negative correlation between ADMA and NO (r ¼ À0.515, P ¼ 0.003 and r ¼ À0.389, P ¼ 0.034, respectively). In NT subjects, there was no correlation between these two parameters (r ¼ À0.287, P ¼ 0.124). The negative correlation between ADMA and NO was stronger in WCH group than HT group. Although NO levels were lower in HTs than WCHs and ADMA levels were higher in HTs than WCHs, the negative correlation between these two parameters were more pronounced in WCH group.
Discussion
Endothelial dysfunction is common in patients with apparent coronary atherosclerosis or patients with cardiovascular risk factors. 25, 26 Also, endothelial dysfunction is thought to be a marker of future cardiovascular events in patients with hypertension. In a number of studies, endothelial dysfunction in HT patients was found out as decreased release of nitric oxide or increased production of endothelin. 27, 28 There are very few studies concerning endothelial dysfunction in WCH and they are controversial. 18, 19, 29 NO is a free radical that was considered as the major endothelium-derived relaxing factor and was found to be reduced in patients with essential hypertension. [30] [31] [32] As this pathologic alteration becomes manifest in the earliest stage of hypertension, endothelial dysfunction may represent an initial factor predisposing to atherogenesis. 10 In recent studies, plasma NO levels were evaluated also in WCH as an indicator of endothelial dysfunction. Pierdomenico et al found that WCH subjects Table 3 Plasma NO, ADMA levels in groups In our previous study, NO levels of WCH subjects were significantly lower than NTs but higher than sustained HTs. 19 In this previous study, the increased levels of endothelin-1, vascular endothelial growth factor and decreased NO levels were associated with endothelial dysfunction and abnormal angiogenesis, although the degree of these changes were not as severe as observed in HT population.
ADMA, which is an endogenous competitive inhibitor of NOS, has been suggested to be a marker of endothelial dysfunction and a predictor of cardiovascular mortality. [7] [8] [9] [10] [11] ADMA competitively inhibits the enzymatic synthesis of NO from Larginine 33 and attenuates endothelium-dependent relaxation. 34 In recent studies, it has been demonstrated that patients with hypertension, hyperlipidaemia, hyperhomocysteinaemia, coronary artery disease have increased plasma levels of ADMA. [9] [10] [11] [12] [13] In the study of Takiuchi et al, 10 plasma ADMA was found to play a major role in endothelial dysfunction in hypertensive patients, independent of insulin resistance or left ventricular hypertrophy. But the ADMA levels in WCH has not been previously studied.
In recent studies, ADMA was measured by high performance liquid chromatography (HPLC). [9] [10] [11] [12] [13] In this present study, ADMA was determined by sandwich ELISA procedure because this method was found to be a precise and easy immunoassay in contrast to the existing methods, such as HPLC and gas chromatography. 24 In our study, we found that ADMA levels in WCH patients were higher than NTs and lower than HTs. In our previous study, NO levels of WCHs were between NTs and HTs. In this present study, we evaluated the ADMA levels in the same patients of our previous study. The plasma NO and ADMA levels were studied from the same blood sample. We found that plasma ADMA levels were significantly higher in WCH group than in the NT group. It was also significantly higher in the HT group than in the NTs. There was a significant difference between the HT and WCH groups. The WCH subjects had significantly higher levels of NO than the HT and significantly lower values than the NT. These findings are in accordance with our previous study, which showed endothelial dysfunction in WCH. 19 In Table 4 , it is summarized what is known about endothelial dysfunction in sustained HT and WCH and what this study adds. 19, 28, 32, [35] [36] [37] [38] [39] Does the difference in circulating plasma ADMA levels from NT, WCH and HT subjects influence endothelial NO production? There was a strong negative correlation between ADMA and NO levels in both groups. In WCH and HT group, there was a negative correlation between ADMA and NO. In NT subjects, there was no correlation between these two parameters. The negative correlation between ADMA and NO was stronger in WCH group than HT group. These findings may suggest that decreased NO levels in WCH may be due to reduction of the activity of the endothelial NOS by ADMA. In addition, we think that in the pathophysiology of the decrease of NO levels in sustained HT not only the inhibitor effect of ADMA on NO but also other factors such as increased vascular formation of oxygen-derived free radicals may be involved.
It is recognized that neuronal production of NO also influences cardiovascular homeostasis through its action as a neuromodulator within the autonomic nervous system. Overall NO has been shown to have sympatho-inhibitory and vagotonic effects, acting by both central and peripheric mechanisms. Sympathetic overactivity, coupled with the permissive role of depressed level of baroreflex-mediated cardiac vagal control, may play a significant role in the genesis of human hypertension. 40 WCH is a clinical situation where sympathetic activity is frequently enhanced. But sympathetic hyperactivity in WCH is not as great as that in HT. 41, 42 These previous findings may explain the lesser degree of increase of NO and ADMA levels in our WCH patients than our HT group.
On the other hand, shear stress stimulates ADMA release as well as endothelial NOS activity in vascular endothelial cells. 43 Thus, raised ADMA in WCH patients may be the expression of mildly raised blood pressure values.
In conclusion, decreased NO and increased ADMA levels in our WCH patients may show the presence of endothelial dysfunction in WCH. Our data indicate also that WCH represent an intermediate group between NT and HT when endothelial dysfunction is concerned. 32, 35 Decrease in arterial compliance 36 Changes in ET-1, NO, vWF, e-selectin, VEGF, P-selectin. 19, 28, [37] [38] [39] (b) What our study adds Increase in ADMA in WCH ET-1: endothelin; NO: nitric oxide; vWF: von Willbrand factor; VEGF: vascular endothelial growth factor; WCH: white coat hypertension; ADMA: asymmetric dimethylarginine.
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